Skip to main content

NOTICE: Due to a lapse in annual appropriations, most of this website is not being updated. Learn more.

Form submissions will still be accepted but will not receive responses at this time. Sections of this site for programs using non-appropriated funds (such as NVLAP) or those that are excepted from the shutdown (such as CHIPS and NVD) will continue to be updated.

U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Improving patient outcomes with regenerative medicine: How to move the needle forward in cell manufacturing, standards, 3D bioprinting, AI enabled automation, education and training

Published

Author(s)

Carl Simon, Josh Hunsberger, Claudia Zylberberg, Preveen Ramamoorthy, Thomas Tubon, Crystal Ruff, Ram Bedi, Kurt Gielen, Lynn Fisher, Jed Johnson, Priya Barankiak, Behzad Mahdavi, Michael Hadjisavas, Shannon Eaker, Cameron Miller

Abstract

Regenerative Medicine Manufacturing Society (RMMS), is the first and only professional society dedicated specifically towards advancing manufacturing solutions for the field of regenerative medicine. RMMS' vision is to provide greater patient access to regenerative medicine therapies through innovative manufacturing solutions. Our mission is to identify unmet needs and gaps in regenerative medicine manufacturing and catalyze the generation of new ideas and solutions by parting with private and public stakeholders. We aim to accomplish our mission through outreach and education programs and securing grants for public-private collaborations in regenerative medicine manufacturing. This perspective article will cover four impact areas that the society's leadership team has identified as critical, which include: (a) cell manufacturing and scale up/out respectively for allogeneic and autologous cell therapies, (b) standards, (c) 3D bioprinting, and (d) artificial intelligence -enabled automation (AI). In addition to covering these areas and ways in which the society intends to advance the field in a collaborative nature, we will also discuss education and training. This is an area that is critical for communicating the current challenges, developing solutions to accelerate the commercialization of the latest technological advances, as well as, growing the work force in this rapidly expanding sector of regenerative medicine.
Citation
Journal of Biomedical Materials Research Part B-Applied Biomaterials

Keywords

regenerative medicine, biomanufacturing, standards, additive manufacturing

Citation

Simon, C. , Hunsberger, J. , Zylberberg, C. , Ramamoorthy, P. , Tubon, T. , Ruff, C. , Bedi, R. , Gielen, K. , Fisher, L. , Johnson, J. , Barankiak, P. , Mahdavi, B. , Hadjisavas, M. , Eaker, S. and Miller, C. (2020), Improving patient outcomes with regenerative medicine: How to move the needle forward in cell manufacturing, standards, 3D bioprinting, AI enabled automation, education and training, Journal of Biomedical Materials Research Part B-Applied Biomaterials, [online], https://doi.org/10.1002/sctm.19-0389, https://tsapps.nist.gov/publication/get_pdf.cfm?pub_id=929159 (Accessed October 13, 2025)

Issues

If you have any questions about this publication or are having problems accessing it, please contact [email protected].

Created June 17, 2020, Updated September 29, 2025
Was this page helpful?